About the Session
New Approach Methodologies (NAMs) are reshaping how researchers study human biology, evaluate therapeutics and reduce reliance on animal testing. As interest in vitro human-relevant 3D models grows, so does the conversation around biological relevance, reproducibility, scalability, validation and what is needed to support broader adoption.
In this roundtable, experts will discuss where human-relevant in vitro models can have the greatest impact across biomedical research and the drug development workflow, what is driving their adoption, and what is still holding it back. The conversation will explore how enabling technologies, including 3D bioprinting, can support the development and wider use of these models, as well as what is needed to translate promising approaches into reliable, scalable and decision-relevant research tools.
Panelists
Biography
Biography
Biography
Biography
Pelin Candarlioglu is a translational scientist and regulatory strategist specialising in advanced human-relevant in vitro models. With over 20 years of experience across academia, biotechnology and pharma, she has extensive expertise in microphysiological systems (MPS) and the development of fit-for-purpose models for drug discovery and safety assessment.
She is internationally recognised for advancing the qualification and regulatory adoption of New Approach Methodologies (NAMs). Pelin founded the Regulatory Subgroup of the IQ MPS Affiliate, chairs the EUROoCS Industry Advisory Board, and has worked with organizations including the FDA, EMA and JRC-ECVAM to advance the acceptance of human-relevant models.
Information
- 1 December 2026
- 4:30 p.m. CET | 3:30 p.m. GMT | 10:30 a.m. EST | 7:30 a.m. PST





